lomustine / Generic mfg. - LARVOL DELTA

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. (PubMed, J Clin Oncol) - P3 | "Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH-mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action."

Journal • P3 data • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Efficacy of vorasidenib in patients with IDH-mutant gliomas previously treated with ivosidenib (ESMO-TAT 2026) - "Treatments received prior to ivosidenib included surgical resection (23, 79%), radiation (16, 55%), temozolomide (15, 52%), PCV (4, 14%) bevacizumab (3, 10%), lomustine (2, 7%) and pembrolizumab (1, 3%). Vorasidenib demonstrated clinical efficacy and tolerability in patients with IDH-mutant gliomas previously treated with ivosidenib. Notably, patients who transitioned due to FDA approval or toxicity maintained disease stability, while a subset of those with progression on ivosidenib achieved stabilization with vorasidenib. These findings support vorasidenib as a viable therapeutic option following ivosidenib exposure."

Clinical • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • IDH1

Self-made matrix: Tumor-derived Laminin-α5 supports pancreatic cancer cell survival and metastatic persistence (AACR 2026) - "To uncover therapeutic vulnerabilities, connectivity mapping through the iLINCS platform identified an FDA-approved compound, Lomustine, which reduced LAMA5 expression and markedly inhibited the growth of mouse and human PDAC organoids. Our findings collectively show that PDAC cells secrete LAMA5 to build a self-made matrix microenvironment that supports survival, adhesion, and metastatic persistence. Tumor-intrinsic LAMA5 redefines the tumor-stroma paradigm, enabling microenvironmental autonomy and anoikis-resistance, and highlights potential targets for intervention in PDAC."

Metastases • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • ITGA6 • ITGB4 • KRAS • LAMA5

Comparative analysis of therapy responses and stem cell marker expression in glioblastoma neurospheres verus monolayer cultures using imaging, cytotoxicity assays, and flow cytometry (AACR 2026) - "Here, we sought to further characterize the phenotype of U-87 MG-Luc2 cells grown in 2D or as neurospheres and to assess their drug sensitivity in vitro and as xenografts. U-87 MG-Luc2 cells grown in 2D or as neurospheres were treated with temozolomide, lomustine, and bortezomib, individually and in combination, to assess drug sensitivity in vitro. These findings suggest that 3D neurosphere models more accurately reflect the in vivo tumor environment and drug response, while 2D monolayers remain a valuable tool for initial therapeutic screening. Neurosphere culture conditions impacted U-87 MG-Luc2 GSC surface marker expression. Tracking changes in frequency and expression of GSC markers after drug treatment may be useful for selecting promising drug candidates."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CD133 • ITGA6

COMPARISON OF CARMUSTINE-, LOMUSTINE-, AND NITROSOUREA-FREE CONDITIONING REGIMENS FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN LYMPHOMA: RESULTS FROM THE BRAZILIAN REGISTRY (EBMT 2026) - "In this large national cohort, outcomes after auto-HCT for lymphoma were comparable across carmustine-, lomustine-, and nitrosourea-free conditioning regimens, supporting their interchangeability when specific agents are unavailable."

B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

COULD PROPHYLACTIC NASOGASTRIC TUBE FEEDING REDUCE WEIGHT LOSS FOR PATIENTS UNDERGOING HIGH-TOXICITY CONDITIONING REGIMENS DURING AUTOLOGOUS STEM CELL TRANSPLANT? (EBMT 2026) - " Three hundred and eighty four patient were included, 60% male, median age 58 years, 69% had multiple myeloma, 21% Non-Hodgkin lymphoma, 51% were conditioned with melphalan 200, 20% with L(B)EAM (lomustine or carmustine with cytarabine, etoposide and melphalan), 19% with melphalan 140, 10% with TT-BNCU (thiotepa and carmustine). Haematological cancer patients undergoing auto-SCT with TT-BNCU or L(B)EAM conditioning regimens are at significantly higher risk of early weight loss and longer hospital stay compared to those receiving melphalan 200 and 140. These results highlight a potential role for prophylactic nasogastric tube feeding in patients receiving high-toxicity regimens to minimise unintentional weight loss and support nutritional recovery throughout auto-SCT to reduce length of stay. Further prospective research is warranted to evaluate the feasibility, safety and long-term impact of prophylactic nasogastric tube feeding in patients receiving high-toxicity..."

Clinical • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

COULD PROPHYLACTIC NASOGASTRIC TUBE FEEDING REDUCE WEIGHT LOSS FOR PATIENTS UNDERGOING HIGH-TOXICITY CONDITIONING REGIMENS DURING AUTOLOGOUS STEM CELL TRANSPLANT? (EBMT 2026) - " Three hundred and eighty four patient were included, 60% male, median age 58 years, 69% had multiple myeloma, 21% Non-Hodgkin lymphoma, 51% were conditioned with melphalan 200, 20% with L(B)EAM (lomustine or carmustine with cytarabine, etoposide and melphalan), 19% with melphalan 140, 10% with TT-BNCU (thiotepa and carmustine). Haematological cancer patients undergoing auto-SCT with TT-BNCU or L(B)EAM conditioning regimens are at significantly higher risk of early weight loss and longer hospital stay compared to those receiving melphalan 200 and 140. These results highlight a potential role for prophylactic nasogastric tube feeding in patients receiving high-toxicity regimens to minimise unintentional weight loss and support nutritional recovery throughout auto-SCT to reduce length of stay. Further prospective research is warranted to evaluate the feasibility, safety and long-term impact of prophylactic nasogastric tube feeding in patients receiving high-toxicity..."

Clinical • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

COMPARISON OF CARMUSTINE-, LOMUSTINE-, AND NITROSOUREA-FREE CONDITIONING REGIMENS FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN LYMPHOMA: RESULTS FROM THE BRAZILIAN REGISTRY (EBMT 2026) - "In this large national cohort, outcomes after auto-HCT for lymphoma were comparable across carmustine-, lomustine-, and nitrosourea-free conditioning regimens, supporting their interchangeability when specific agents are unavailable."

B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

COULD PROPHYLACTIC NASOGASTRIC TUBE FEEDING REDUCE WEIGHT LOSS FOR PATIENTS UNDERGOING HIGH-TOXICITY CONDITIONING REGIMENS DURING AUTOLOGOUS STEM CELL TRANSPLANT? (EBMT 2026) - " Three hundred and eighty four patient were included, 60% male, median age 58 years, 69% had multiple myeloma, 21% Non-Hodgkin lymphoma, 51% were conditioned with melphalan 200, 20% with L(B)EAM (lomustine or carmustine with cytarabine, etoposide and melphalan), 19% with melphalan 140, 10% with TT-BNCU (thiotepa and carmustine). Haematological cancer patients undergoing auto-SCT with TT-BNCU or L(B)EAM conditioning regimens are at significantly higher risk of early weight loss and longer hospital stay compared to those receiving melphalan 200 and 140. These results highlight a potential role for prophylactic nasogastric tube feeding in patients receiving high-toxicity regimens to minimise unintentional weight loss and support nutritional recovery throughout auto-SCT to reduce length of stay. Further prospective research is warranted to evaluate the feasibility, safety and long-term impact of prophylactic nasogastric tube feeding in patients receiving high-toxicity..."

Clinical • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

131I-TLX-101-003: A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma (clinicaltrialsregister.eu) - P2/3 | N=30 | Not yet recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited

New P2/3 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Durable Disease Control with Erdafitinib Plus Tumor Treating Fields in FGFR3::TACC3–Positive Glioblastoma (DKK 2026) - "He received standard therapy with 60 Gy radiotherapy, lomustine plus temozolomide and continuous Tumor Treating Fields (TTF). This case illustrates unprecedented disease control with erdafitinib plus TTF in FGFR3::TACC3-positive GBM, markedly surpassing expected post-recurrence outcomes. Preclinical data suggest FGFR inhibition enhances TTF efficacy by suppressing adaptive signaling, impairing DNA repair, and sensitizing GBM stem cells to mitotic catastrophe. Together, this clinical and mechanistic evidence highlights FGFR inhibition plus TTF as a promising therapeutic strategy warranting prospective evaluation in molecularly defined GBM."

Brain Cancer • Dental Disorders • Dermatitis • Glioblastoma • Immunology • Infectious Disease • Oncology • Solid Tumor • Xerostomia • FGFR3 • MGMT • TACC3

Response to Next Intervention After Off-label Ivosidenib Treatment Failure in Patients With Mutant IDH Low Grade Glioma (AAN 2026) - "In addition to ivosidenib, prior treatments included maximal safe resection (n=7), temozolomide (n=4), and lomustine (n=1). In this real-world cohort, most patients with IDH1-mutant LGG achieved radiographic and clinical stability following progression on ivosidenib with using next-line chemotherapy and RT. These findings support the feasibility of cytotoxic strategies following IDHi treatment failure."

Clinical • Astrocytoma • Brain Cancer • Glioma • Oligodendroglioma • Solid Tumor • IDH1

Comparative Efficacy and Safety of Temozolomide-based Versus Lomustine-based Chemotherapy Regimens in Patients With Glioblastoma Multiforme (AAN 2026) - "CCNU-based regimens may modestly improve survival over TMZ, particularly in MGMT-methylated, newly diagnosed GBM, without added toxicity. These findings support genotype-guided chemotherapy selection and highlight the need for biomarker-stratified trials to refine precision-based GBM treatment."

Clinical • Brain Cancer • Glioblastoma • Solid Tumor • MGMT

Larotrectinib for NTRK Amplification in Glioblastoma: Case Report (AAN 2026) - " A 51-year-old man with multifocal, MGMT-unmethylated glioblastoma underwent resection followed by chemoradiation with temozolomide, six cycles of adjuvant temozolomide, and tumor treating fields...Third-line lomustine and bevacizumab were subsequently initiated... In patients with glioblastoma with NTRK amplification, this case suggests limited benefit with treatment with Larotrectinib as compared to previously demonstrated significant efficacy in NTRK fusion–positive gliomas. These findings highlight the necessary requirements to distinguish between NTRK fusions and amplifications when clinically considering targeted TRK inhibition. This case reports bridges the importance of molecular profiling to guide therapy selection."

Case report • Clinical • Brain Cancer • Glioblastoma • Glioma • Solid Tumor • MGMT • NTRK • NTRK2

Bridging Neuro-oncology and Gender-affirming Care: Clinical and Treatment Insights From a Multi-site Mayo Clinic Cohort (AAN 2026) - "Tumor-directed treatments included surgery (n=10), radiation therapy (n=6), and systemic therapy (n=7, using temozolomide, lomustine, ivosidenib, vorasidenib, lapatinib, bevacizumab). GAHT was well tolerated and not associated with accelerated tumor progression in most cases. The temporal association between estrogen exposure and symptom fluctuation in an NF2-associated meningioma highlights the need for individualized risk assessment and multidisciplinary care in this understudied population."

Clinical • Astrocytoma • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Meningioma • Ocular Inflammation • Oligodendroglioma • Ophthalmology • Optic Neuritis • Pituitary Gland Carcinoma • Solid Tumor • BRAF

Charles Bonnet Syndrome After Radiation (AAN 2026) - "Few cases of CBS as a side effect of radiation have been described but it is likely under reported.Design/ N/A Case Report: A 33-year-old male with a right frontal/ corpus callosum grade 2 oligodendroglioma, IDH MT, 1p/19q codeleted underwent a subtotal resection followed by radiation alone and four cycles of procarbazine, lomustine, and vincristine chemotherapy. Our case underscores the potential for CBS to emerge as a complication of radiation, especially in patients experiencing cognitive decline. Although rare, clinicians should consider CBS as a complication of RION."

Brain Cancer • Glioma • Head and Neck Cancer • Ocular Inflammation • Oligodendroglioma • Ophthalmology • Optic Neuritis • Rare Diseases • Solid Tumor

A network-driven computational framework for identifying FDA-approved drug repurposing across heterogeneous brain cancers. (PubMed, Front Mol Biosci) - "As a result, three repurposed drugs were identified as priorities: (i) mefloquine (reference drug: vorasidenib citrate), (ii) clofibric acid (reference drug: carmustine), and armillarisin A (reference drug: lomustine). These results also suggest repurposing candidates for synergistic combinations across different brain tumors. The two applications developed in this work are freely accessible and in the public domain at https://assay.smallmoles.com/escorwin."

FDA event • Heterogeneity • Journal • Brain Cancer • Oncology • Solid Tumor • BRAF • CDK1 • EGFR • KDR • PDGFRA • TERT • TP53

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma (clinicaltrials.gov) - P2/3 | N=360 | Active, not recruiting | Sponsor: Universitätsklinikum Hamburg-Eppendorf | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2024 ➔ Dec 2026 | Trial primary completion date: Apr 2024 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Brain Cancer • Medulloblastoma • Oncology • Pediatrics • Solid Tumor • MYCN

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma (clinicaltrials.gov) - P2/3 | N=360 | Recruiting | Sponsor: Universitätsklinikum Hamburg-Eppendorf | Not yet recruiting ➔ Recruiting

Enrollment open • Brain Cancer • Medulloblastoma • Oncology • Pediatrics • Solid Tumor • MYCN

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma (clinicaltrials.gov) - P2/3 | N=360 | Not yet recruiting | Sponsor: Universitätsklinikum Hamburg-Eppendorf

New P2/3 trial • Brain Cancer • Medulloblastoma • Oncology • Pediatrics • Solid Tumor • MYCN

Adaptive, Clinically Guided Multimodal Therapy with Supportive Drug Sensitivity Testing in a Dog with Hepatic Neuroendocrine Carcinoma: A Case Report. (PubMed, Animals (Basel)) - "Sequential systemic therapies-including doxorubicin, mitoxantrone with lomustine and prednisolone, and subsequently toceranib-were administered based on clinical response assessment using imaging (VCOG RECIST), hematologic monitoring, and quality-of-life evaluation. Sustained stable disease was observed following transition to toceranib with continued adjunct immunomodulatory therapy; however, the independent contribution of each treatment component cannot be determined. This case highlights the feasibility of iterative treatment refinement in rare canine malignancies and emphasizes that DST findings should be integrated cautiously within a broader clinical decision-making framework."

Journal • Endocrine Cancer • Gastrointestinal Neuroendocrine Carcinoma • Hepatocellular Cancer • Neuroendocrine Carcinoma • Oncology • Solid Tumor

Mapping the molecular landscape of glioblastoma: Pathogenesis, therapeutic targets and bioactive interventions. (PubMed, Crit Rev Oncol Hematol) - "First-line therapy includes surgery followed by the primary chemotherapeutic agent temozolomide in combination with radiotherapy. Other drugs, including bevacizumab, carmustine, and the combination of procarbazine, lomustine, and vincristine, offer limited benefits...This review emphasizes the importance of systematic molecular mapping of GBM progression to identify the genetic, metabolic, and regulatory mechanisms that sustain malignancy and therapeutic resistance. Additionally, it also discusses the multimodal mechanism of natural bioactives that align with the overlapping molecular targets and pathways to overcome the limitations of single-target therapies, offering translational combination therapies that provide more effective and precision-based interventions for GBM management."

Journal • Review • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss (clinicaltrials.gov) - P3 | N=225 | Recruiting | Sponsor: Children's Oncology Group | Trial completion date: Dec 2027 ➔ Dec 2029 | Trial primary completion date: Dec 2027 ➔ Dec 2029

Trial completion date • Trial primary completion date • Brain Cancer • Medulloblastoma • Oncology • Otorhinolaryngology • Solid Tumor • GLI2 • MYCN

NRG-BN011: Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma (clinicaltrials.gov) - P3 | N=265 | Active, not recruiting | Sponsor: NRG Oncology | Suspended ➔ Active, not recruiting

Enrollment closed • Brain Cancer • Glioblastoma • Gliosarcoma • Oncology • Sarcoma • Solid Tumor • IDH1 • MGMT

LEAHRN: Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma (clinicaltrials.gov) - P2 | N=45 | Active, not recruiting | Sponsor: Children's Oncology Group | Trial completion date: Jun 2027 ➔ Mar 2028 | Trial primary completion date: Jun 2027 ➔ Mar 2028

Trial completion date • Trial primary completion date • Brain Cancer • Medulloblastoma • Oncology • Solid Tumor • CTNNB1 • MYCN